Transdermal 17Beta-estradiol, progesterone — Competitive Intelligence Brief

Transdermal 17Beta-estradiol, progesterone (Transdermal 17Beta-estradiol, progesterone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormone replacement therapy (HRT). Area: Women's Health / Endocrinology.

phase 3 Hormone replacement therapy (HRT) Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR) Women's Health / Endocrinology Small molecule

Target snapshot

Transdermal 17Beta-estradiol, progesterone (Transdermal 17Beta-estradiol, progesterone) — Massachusetts General Hospital. This transdermal combination replaces estrogen and progesterone to restore hormonal balance in menopausal or postmenopausal women.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Transdermal 17Beta-estradiol, progesterone TARGET	Transdermal 17Beta-estradiol, progesterone	Massachusetts General Hospital	phase 3	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR)
Estradiol/norethindrone acetate	Estradiol/norethindrone acetate	Myovant Sciences GmbH	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha and beta; progesterone receptor
estradiol plus progesterone	estradiol plus progesterone	Peking Union Medical College Hospital	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR)
Transdermal strogen	Transdermal strogen	Parc de Salut Mar	marketed	Hormone replacement therapy (HRT) / Estrogen replacement	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
estrogen therapy	estrogen therapy	Beni-Suef University	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ)
Estradiol + Medroxy Progesterone Acetate	Estradiol + Medroxy Progesterone Acetate	Erasmus Medical Center	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR)
Estracomb TTS	Estracomb TTS	Anna Posadzy-Małaczyńska	marketed	Hormone replacement therapy (HRT)	Estrogen receptor (ER-α, ER-β) and progesterone receptor (PR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormone replacement therapy (HRT) class)

1. Anna Posadzy-Małaczyńska · 1 drug in this class
2. Beni-Suef University · 1 drug in this class
3. Brigham and Women's Hospital · 1 drug in this class
4. El Shatby University Hospital for Obstetrics and Gynecology · 1 drug in this class
5. Erasmus Medical Center · 1 drug in this class
6. Massachusetts General Hospital · 1 drug in this class
7. Myovant Sciences GmbH · 1 drug in this class
8. Peking Union Medical College Hospital · 1 drug in this class
9. Scientific Research Institute of Public Health, Russian Federation · 1 drug in this class
10. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 drug in this class